ALT

Business Context and Reporting Period

Company: PharmAthene, Inc. (Note: Request metadata listed "Altimmune, Inc.", but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: PharmAthene is a biopharmaceutical company focused on developing biodefense countermeasures against biological and chemical weapons. Its lead product candidates include SparVax (anthrax vaccine), Valortim (anthrax monoclonal antibody), and Protexia (nerve agent protectant). The company relies heavily on U.S. government contracts and grants for revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 44% ($2.4 million) compared to Q1 2009. This was primarily due to the completion of the first phase of the Protexia contract with the Department of Defense (DoD) in 2009, with no new phase funding secured for 2010. Revenue from the SparVax program increased slightly due to a contract modification, while Valortim revenue remained relatively flat.
• Increased Net Loss: Net loss widened by $1.9 million to $7.94 million. This was driven by the revenue decline and an increase in General and Administrative (G&A) expenses, which included a $588,000 allowance for doubtful accounts related to the potential wind-down of a third-generation anthrax vaccine program with NIAID.
• Liquidity Deterioration: Cash and cash equivalents dropped significantly from $2.67 million at year-end 2009 to $0.74 million at March 31, 2010. The company liquidated short-term investments to fund operations.
• Equity Deficit: The company moved from positive stockholders' equity ($1.88 million) to a deficit of $(5.21) million due to the accumulated net loss for the quarter.

Guidance, Outlook, Risks, and Unusual Items

• Contract Uncertainties:
  • SparVax: A contract modification allowing up to $61 million in funding was suspended in March 2010 due to a third-party bid protest filed with the GAO. A decision is expected by June 11, 2010.
  • NIAID Contract: NIAID raised concerns regarding performance on a $13.2 million third-generation anthrax vaccine contract and notified the company in April 2010 that it is considering termination for default. Management believes an agreement on termination is likely.
  • Protexia: The DoD has not yet decided on funding for the next phase of development, though a decision is anticipated before the end of Q3 2010.
• Valortim Clinical Hold: The FDA placed a partial clinical hold on the Phase I trial of Valortim in late 2009 due to adverse reactions. BARDA has paused negotiations for advanced development funding until the hold is lifted.
• Liquidity Outlook: Management states it does not anticipate requiring additional funding to continue current operations through the end of 2010 based on expected government receipts. However, the company may need to raise capital to fund operations beyond 2010 or to expand the business.
• Management Changes: In April 2010, David P. Wright resigned as CEO. Eric I. Richman was appointed interim CEO in May 2010.
• Legal Proceedings: The company is involved in ongoing litigation with Siga Technologies, Inc. regarding rights to the drug candidate SIGA-246. A hearing on a motion for summary judgment is anticipated in June or July 2010.
• Subsequent Event: In April 2010, the company completed a public offering of common stock and warrants, generating gross proceeds of $2.5 million.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $0.74 million cash balance plus the $2.5 million raised in April 2010 to cover operating expenses until the next expected government funding or financing event.
• Contract Status: Monitor the outcome of the GAO bid protest regarding the SparVax contract modification and the final decision on the NIAID contract termination.
• Valortim Clinical Hold: Track the resolution of the FDA partial clinical hold on Valortim, as this is a prerequisite for future BARDA funding.
• Debt Obligations: Review the terms of the $18.3 million convertible notes (maturing July 2011) and the potential dilution from conversion or warrant exercises.
• Accounts Receivable: Assess the collectability of the $16.9 million in total receivables, particularly given the $588,000 allowance for doubtful accounts already recorded.